D^b RMA-S stabilization assay. by Mariah Hassert (5746874)

Changes in pulmonary myeloid cell populations in MA-ARDS and its resolution. by Emilie Pollenus (10147748)

Activation of TRPV1 receptors in the ARC reduces food intake. by Jae Hoon Jeong (215351)

The system under study. by Abdallah Aldosary (21370131)

Blood concentrations of VEGF-A121, VEGF-A165, and VEGF-A pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

TS1 parameters. by Abdallah Aldosary (21370131)

TS3 parameters. by Abdallah Aldosary (21370131)

Superhydrophobic/Superhydrophilic Janus Evaporator for Extreme High Salt-Resistance Solar Desalination by an Integrated 3D Printing Method by Congcan Shi (4768068)

“…The emerging solar desalination technology has incomparable advantages for providing a clean water solution. However, the issue of salt accumulation on the solar evaporator tops during the steam generation leads to a considerable decrease in the evaporation rate. …”

Superhydrophobic/Superhydrophilic Janus Evaporator for Extreme High Salt-Resistance Solar Desalination by an Integrated 3D Printing Method by Congcan Shi (4768068)

“…The emerging solar desalination technology has incomparable advantages for providing a clean water solution. However, the issue of salt accumulation on the solar evaporator tops during the steam generation leads to a considerable decrease in the evaporation rate. …”

Choroidal vascularity changes in idiopathic central serous chorioretinopathy after half-fluence photodynamic therapy by Dae Joong Ma (5687885)

“…The vascular proportions in Sattler’s and Haller’s layers did not show a significant decrease at 6 weeks (Sattler’s: 49.7% ± 17.3%, <i>P</i> = 0.052 and Haller’s: 58.3% ± 12.9%, <i>P</i> = 0.558) but decreased significantly at 6 months (Sattler’s: 48.9% ± 12.4%, <i>P</i> < 0.001 and Haller’s: 57.7% ± 15.7%, <i>P</i> = 0.027) and 12 months after HF-PDT from the baseline values (Sattler’s: 45.8% ± 10.4%, <i>P</i> < 0.001 and Haller’s: 56.8% ± 15.7%, <i>P</i> < 0.001).…”

HBF design results to minimize <i>P_LOSS</i> in TS1. by Abdallah Aldosary (21370131)

HBF design parameters for TS3. by Abdallah Aldosary (21370131)

HBF design parameters for TS1. by Abdallah Aldosary (21370131)

HBF design results minimize P_LOSS in TS3. by Abdallah Aldosary (21370131)

Microtubule organization in the tegument of <i>M. corti.</i> by Inés Guarnaschelli (18102211)

Changes in pulmonary nonimmune cell populations in MA-ARDS and its resolution. by Emilie Pollenus (10147748)

Immortality with tetraploidy is blocked in quiescent cells with diploidy, diminished H2AX, and no γH2AX foci. by Yuko Atsumi (209964)

“…<b>E.</b> DNA lesion-carryover into the G2-M phases was determined for lesions that spontaneously accumulated in senescent MEFs under Std-3T3 conditions. …”

Bortezomib treatment does not increase weight, locomotion, muscle strength or reduce plasma levels of CK and miRNA. by Zandra Körner (843029)

“…(E) Analysis of CK levels in plasma revealed a significant increase in CK levels in <i>dy</i>^<i>2J</i><i>/dy</i>^<i>2J</i>mice, which was not significantly reduced by bortezomib. …”

Neutralization with additional bevacizumab to serum samples pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

“…<b>d</b> VEGF-A165 concentrations were low in serum samples post-bevacizumab administration and remained low after further addition of bevacizumab. <b>e</b> The percent change in VEGF-A121 concentration with the addition of any (2, 20, or 200 μg/mL) concentration of bevacizumab to serum samples post-bevacizumab administration was significantly less than the percent change in VEGF-A121 concentration with the addition of 2 μg/mL concentration of bevacizumab to serum samples pre-bevacizumab administration (ANOVA: <i>p</i> < 0.0001; Dunnett’s multiple comparisons test: Post+2 μg/mL, <i>p</i> < 0.0001 vs Pre+2 μg/mL; Post +20 μg/mL, <i>p</i> < 0.0001 vs Pre+2 μg/mL; +200 μg/mL, <i>p</i> < 0.0001 vs Pre+2 μg/mL).…”

Age-dependent changes in the thermal stability of nuclear lamin-B and CP190. by Wei-Qi Lin (2518108)